Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular…
– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations…